Senti Biosciences' CEO will present at Chardan's Genetic Medicines Conference, discussing their innovative gene therapy developments.
Quiver AI Summary
Senti Biosciences, Inc., a clinical-stage biotechnology company specializing in next-generation cell and gene therapies, announced that its CEO Timothy Lu will present at the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The company plans to engage with qualified investors through one-on-one meetings during the event. Senti Bio focuses on developing its proprietary Gene Circuit platform to create enhanced therapies targeting cancer and other diseases, with promising preclinical results in manipulating T and NK cells. Interested parties can access a live webcast of Lu's presentation on the company’s website, and Senti Bio encourages ongoing engagement through its online communications.
Potential Positives
- Presentation opportunity at a notable industry conference highlights Senti Bio's growing presence and recognition in the biotechnology space.
- One-on-one meetings with qualified investors may attract interest and investment in Senti Bio's innovative developments.
- Demonstrates Senti Bio's commitment to transparency and investor engagement through live webcasting of the presentation.
- Focus on cutting-edge Gene Circuit technology positions Senti Bio at the forefront of cell and gene therapy advancements, potentially enhancing investor confidence.
Potential Negatives
- None
FAQ
What is the purpose of Timothy Lu's presentation at the conference?
Timothy Lu will discuss Senti Biosciences' advancements in cell and gene therapies using the Gene Circuit platform.
When and where is the 9th Annual Genetic Medicines Conference taking place?
The conference is being held on October 21, 2025, in New York, NY.
How can investors access the live webcast of the presentation?
The live webcast will be available on the Events page of Senti Bio's Investors section on their website.
What is the focus of Senti Biosciences' research and development?
Senti Biosciences focuses on developing next-generation cell and gene therapies for incurable diseases using engineered Gene Circuits.
Where can I find more information about Senti Biosciences?
More information is available on Senti Biosciences’ website at www.sentibio.com and their social media platforms.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNTI Hedge Fund Activity
We have seen 0 institutional investors add shares of $SNTI stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- 8VC GP I, LLC added 0 shares (+0.0%) to their portfolio in Q2 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SNTI Analyst Ratings
Wall Street analysts have issued reports on $SNTI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/08/2025
- Laidlaw & Co. issued a "Buy" rating on 06/06/2025
To track analyst ratings and price targets for $SNTI, check out Quiver Quantitative's $SNTI forecast page.
$SNTI Price Targets
Multiple analysts have issued price targets for $SNTI recently. We have seen 3 analysts offer price targets for $SNTI in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $12.0 on 10/14/2025
- Geulah Livshits from Chardan Capital set a target price of $12.0 on 08/08/2025
- Yale Jen from Laidlaw & Co. set a target price of $5.0 on 06/06/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, MD, PhD, CEO and Co-Founder of Senti Biosciences will present at Chardan’s 9 th Annual Genetic Medicines Conference being held on October 21, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website .
A live webcast of the presentation will be available on the Events page of Investors section of the Company’s website ( www.sentibio.com ).
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website ( www.sentibio.com ), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn . The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
